ICPT earnings call for the period ending December 31, 2020.
News & Analysis: Intercept Pharmaceuticals
ICPT earnings call for the period ending September 30, 2020.
The company's quarterly results were fine, but the more important news from the biopharmaceutical wasn't financial.
The company's share price is down more than 60% for the year, but could positive news on its new nonalcoholic steatohepatitis (NASH) drug make an investor a millionaire?
A better-than-expected quarter helps ease the pain of a recent FDA denial.
ICPT earnings call for the period ending June 30, 2020.
An approval pathway for OCA in treating NASH still exists. But it appears to be a steeper path.
The pharmaceutical company's attempt to get obeticholic acid approved for the lucrative non-alcoholic steatohepatitis market has hit a (perhaps temporary) roadblock.
Shares are taking a step back after the FDA rejected the company's NASH candidate.
These two companies are going after the same target, but which one should you bet on today?